Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Is There a Link Between Graves’ Disease and Thyroid Cancer?

August 23, 2019
By Naveed Saleh, MD, MS
Article

Researchers examined several studies of patients with Graves' Disease to see the prevalence of thyroid cancer in this population.

The existence of thyroid nodules is significantly linked to the prevalence of thyroid cancer in surgically treated patients with Graves’ disease, according to the results of a recent meta-analysis published in Clinical Endocrinology.

“It was previously thought that disorders characterized by hyperthyroidism, such as GD [Graves’ disease], were protective against thyroid cancer,” wrote authors, led by Anastasios Papanastasiou, 3rd Department of Surgery, “AHEPA” University Hospital, Medical School, Aristotle University of Thessaloniki, Greece.

In the study, researchers mined PubMed, Cochrane Library, Scopus, as well as “grey” literature sources, including repositories, catalogues, websites, and conference proceedings of major international congresses, for seven observational studies (n=2,582) involving the prevalence of thyroid cancer in patients with Graves’ disease.

In total, the prevalence of any type of thyroid cancer was 11.5%. Furthermore, the presence of ≥ thyroid nodules in patients with Grave disease was correlated with a heightened risk for thyroid cancer [odds ratio (OR) 5.3, 95% confidence interval (CI) 2.4 –11.6, I2 83%]. On subgroup analysis, no difference in thyroid cancer risk in patients with Graves’ disease was observed relative to to the number of nodules (solitary vs multiple) (OR 1.4, 95% CI 0.9 –2.3, I2 0%).

Although the etiopathology of Graves’ disease remains to be elucidated, it has been linked to genetic and environmental factors, with an annual incidence of 20 - 50 cases per 100,000 people. It is more common in people aged 30-50 years old, with women harboring a six-fold higher risk vs men.

The presentation of solitary or multiple thyroid nodules is a common finding in patients with thyroid disorders. Per the literature, patients with thyroid nodules are at higher risk for thyroid cancer. Of note, ultrasonography used for screening has boosted the incidence of detected thyroid nodules.

Experts once hypothesized that hyperthyroid disorders-including Graves’ disease-were protective vs thyroid cancer (0.15 - 2.5%), but recent studies have shown a higher prevalence of thyroid cancer in patients with Graves’ disease (2.6 - 15%). Moreover, the pathiogenesis of thyroid cancer in patients with Graves’ disease is debated, with some studies reporting a higher rate of lymph node metastasis and death, whereas others have reported the opposite. Of interest, although some meta-analyses have examined thyroid cancer risk in patients with Grave disease, no study has analyzed assessed thyroid nodules as a risk factor for thyroid cancer in such patients.

In addition to being retrospective, the current study had limitations.

“High heterogeneity was noticed among studies for the primary outcome, mainly because of confounding bias. More specifically, the patient characteristics and the indications for surgery varied among studies. For this reason, a sensitivity analysis was performed,” wrote the authors.

“The preoperative detection of thyroid nodules was associated with a higher prevalence of thyroid cancer in patients with GD,” they concluded. “However, the retrospective data of the selected studies had led to confounding bias and high heterogeneity. Consequently, further prospective research on cancer risk in patients with GD is required to confirm this finding.”

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content
Advertisement

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article

Data from a phase 1/2a trial showed that plixorafenib-based care achieved a median PFS of 63.9 months in patients with BRAF-altered thyroid cancers.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.

Thyroidectomy Shows Noninferiority Without Radioiodine in Thyroid Cancer

Roman Fabbricatore
February 5th 2025
Article

A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Tim Cortese
November 1st 2024
Article

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Related Content
Advertisement

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article

Data from a phase 1/2a trial showed that plixorafenib-based care achieved a median PFS of 63.9 months in patients with BRAF-altered thyroid cancers.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.

Thyroidectomy Shows Noninferiority Without Radioiodine in Thyroid Cancer

Roman Fabbricatore
February 5th 2025
Article

A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Tim Cortese
November 1st 2024
Article

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.